"LIMITED PROMOTION" OF UNAPPROVED DEVICES AT TRADE SHOWS
This article was originally published in The Gray Sheet
Executive Summary
"LIMITED PROMOTION" OF UNAPPROVED DEVICES AT TRADE SHOWS would be allowed by FDA under the latest draft of a compliance policy guide governing promotion of devices that are pending premarket approval or 510(k) clearance, according to agency staffers. However, the policy, currently under review by FDA's Office of General Counsel, makes two stipulations regarding disclosure of product status: first, trade show displays must state prominently that the product is awaiting FDA clearance/approval and is not currently being marketed in the U.S., and second, the firm may not claim or suggest that the device is "safe and effective."
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.